Eculizumab: A guide to its Use in paroxysmal nocturnal hemoglobinuria

BioDrugs

Volumn 26, Issue 2, 2012, Pages 125-130

  Keating, Gillian M ^a   Lyseng Williamson, Katherine A ^a   McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; HEMOGLOBIN; PLACEBO;

ARTICLE; CHRONIC KIDNEY DISEASE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; ETHNIC GROUP; FATIGUE; HEADACHE; HUMAN; INTRAVASCULAR HEMOLYSIS; MENINGOCOCCOSIS; NAUSEA; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PERIPHERAL EDEMA; PREGNANCY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; RHINOPHARYNGITIS; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HUMANS;

EID: 84857893047     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11208420-000000000-00000     Document Type: Article

References (17)

1. McKeage K. Eculizumab: A review of its use in paroxysmal nocturnal haemoglobinuria. Drugs 2011; 71 (17): 2327-45
2. Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007 Nov; 25 (11): 1256-64
3. Soliris® (eculizumab) concentrated solution for intravenous infusion: US prescribing information. Chesire (CT): Alexion Pharmaceuticals, Inc., 2011 Sep
4. Soliris® 300 mg concentrate for solution for infusion: Summary of product characteristics. London: European Medicines Agency, 2011 Dec 15
5. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004 Feb 5; 350 (6): 552-9
6. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 Sep 21; 355 (12): 1233-43
7. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 Feb 15; 111 (4): 1840-7
8. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007 Dec 1; 110 (12): 4123-8
9. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival. Blood 2011 Jun 23; 117 (25): 6786-92
10. Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010 Aug; 85 (8): 553-9
11. Reiss U, Schwartz J, Sakamoto K, et al. Safety and efficacy of eculizumab in children and adolescents with paroxysmal nocturnal hemglobinuria [abstract no. P1034 plus poster]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 10-13; San Diego (CA)
12. Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010 May; 149 (3): 446-50
13. Danilov AV, Brodsky RA, Craigo S, et al. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Leuk Res 2010 May; 34 (5): 566-71
14. Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: The AEGIS clinical trial. Int J Hematol 2011 Jan; 93 (1): 36-46
15. Kim JS, Lee JW, Kim BK, et al. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. Korean J Hematol 2010 Dec; 45 (4): 269-74
16. Brodsky RA, de Castro III C, Schrezenmeier H, et al. Long term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH) [abstract no. 4237 plus poster]. 52nd American Society of Hematology Annual Meeting; 2010 Dec 4-7; Orlando (FL)
17. Meningitis in PNH patients treated with eculizumab in clinical trials. Cheshire (CT): Alexion Pharmaceuticals Inc., 2011. (Data on file)